Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | -0.62% | +2.89% | +267.82% |
May. 10 | Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 01 | Kiromic BioPharma, Inc. announced that it has received $2 million in funding | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 1.09M |
---|---|---|---|---|---|
Net income 2022 | -34M | Net income 2023 | -20M | EV / Sales 2022 | - |
Net Debt 2022 | 8.77M | Net Debt 2023 | 12.34M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.08
x | P/E ratio 2023 |
-0.04
x | Employees | 35 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.1% |
1 day | -0.62% | ||
1 week | +2.89% | ||
Current month | +21.44% | ||
1 month | +18.08% | ||
3 months | -7.51% | ||
6 months | +966.67% | ||
Current year | +267.82% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Dahlbeck
FOU | Founder | 62 | 06-08-05 |
Pietro Bersani
CEO | Chief Executive Officer | 56 | 20-05-31 |
Brian Hungerford
DFI | Director of Finance/CFO | 49 | 23-06-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Nagel
CHM | Chairman | 62 | 20-05-31 |
Pamela Misajon
BRD | Director/Board Member | 65 | 23-07-19 |
Pietro Bersani
CEO | Chief Executive Officer | 56 | 20-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 3.2 | -0.62% | 2,773 |
24-05-23 | 3.22 | +2.22% | 360 |
24-05-22 | 3.15 | -2.48% | 445 |
24-05-21 | 3.23 | +4.19% | 4,548 |
24-05-20 | 3.1 | -0.32% | 3,073 |
Delayed Quote OTC Markets, May 24, 2024 at 01:37 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+267.82% | 4.94M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- KRBP Stock